Last reviewed · How we verify
NCT04338126: TCInpatient
Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients
Withdrawn
Phase 2
Last updated 23 April 2021
What this trial tests
Phase 2 trial testing Tranexamic acid in COVID19. Withdrawn.
Timeline
30 September 2021
Primary endpoint
15 December 2021
15 December 2021
31 December 2021
Quick facts
| Lead sponsor | University of Alabama at Birmingham |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Start date | 30 September 2021 |
| Primary completion | 15 December 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Tranexamic acid (Tranexamic Acid) — full drug profile →
- Placebo oral tablet — full drug profile →
Conditions studied
- COVID19 — all drugs for COVID19 →
Sponsor
University of Alabama at Birmingham
Who can join
19 and older, any sex, with COVID19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A controlled trial of the drug tranexamic acid (TXA) in inpatients recently admitted to the hospital with the diagnosis of COVID19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic.
Driggin E, Madhavan MV, Bikdeli B, Chuich T, et al · · 2020 · cited 1272× · PMID 32201335 · DOI 10.1016/j.jacc.2020.03.031 -
Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
Jafarzadeh A, Chauhan P, Saha B, Jafarzadeh S, et al · · 2020 · cited 246× · PMID 32687918 · DOI 10.1016/j.lfs.2020.118102 -
COVID-19 and Cancer: a Comprehensive Review.
Gosain R, Abdou Y, Singh A, Rana N, et al · · 2020 · cited 187× · PMID 32385672 · DOI 10.1007/s11912-020-00934-7 -
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794 -
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2020 · cited 105× · PMID 32717568 · DOI 10.1016/j.drup.2020.100719 -
Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements.
Pandey A, Nikam AN, Shreya AB, Mutalik SP, et al · · 2020 · cited 80× · PMID 32497632 · DOI 10.1016/j.lfs.2020.117883 -
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895 -
Thromboembolic events and Covid-19.
Ribes A, Vardon-Bounes F, Mémier V, Poette M, et al · · 2020 · cited 55× · PMID 32773098 · DOI 10.1016/j.jbior.2020.100735
Verify or expand the search:
- PubMed search for NCT04338126
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tranexamic acid
Trials testing the same drug.
- NCT07278037 — Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage · recruiting
- NCT06599762 — Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia · Phase 2 · recruiting
- NCT06657924 — Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery · Phase 2 · recruiting
- NCT06806241 — Effects of Tranexamic Acid Irrigation on Impacted Third Molar Surgery · recruiting
- NCT06419075 — Tranexamic Acid in Vaginal Reconstructive Surgery · Phase 4 · withdrawn
Other recruiting trials for COVID19
Currently open trials in the same condition.
- NCT07337382 — The Optimising Isolation, Quarantine and Distancing Study for COVID-19 · active not recruiting
- NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting
- NCT04367883 — Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection · recruiting
Other University of Alabama at Birmingham trials
Trials by the same sponsor.
- NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
- NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
- NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
- NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
- NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04338126 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
- Last refreshed: 23 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04338126.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing